Navigation Links
Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
Date:11/30/2009

NEW YORK, Nov. 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration. As part of this collaboration, M.D. Anderson has joined an ongoing Phase I/II clinical trial of SL-401 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

"We are pleased to be involved with Stemline and its innovative programs targeting cancer stem cells," said Hagop Kantarjian, MD, Chairman of the Department of Leukemia at M.D. Anderson. "This clinical trial provides a new option for our patients with AML and MDS."

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have M.D. Anderson, a world class institution and leader in oncology, join the ongoing Phase I/II study in AML and MDS for SL-401 and work with us on additional programs. This is an exciting time for the company as we expand our clinical program, advance our diverse pipeline, and continue to build out our proprietary platforms."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I/II clinical trial. Stemline is also developing a proprietary portfolio of biological and small molecule compounds directed at high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called StemScreen® which the Company has utilized to identify candidate compounds that target cancer stem cells. For more information, please visit the Company's website at www.stemline.com.



Stemline Contact:
Tom Cirrito, PhD
Director of Operations
Stemline Therapeutics, Inc.
Tel: 212-531-5976
Email: tcirrito@stemline.com


SOURCE Stemline Therapeutics, Inc


'/>"/>
SOURCE Stemline Therapeutics, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
2. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
4. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
5. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
6. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
7. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
8. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
9. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
11. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 17, 2017  Bayer announced today ... portfolio will be presented at the 53 rd ... (ASCO), taking place June 2-6 in Chicago ... at ASCO span prostate, colorectal, liver and thyroid cancers, ... from the Phase II CHRONOS-1 trial of copanlisib in ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained ... was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , ... of independent hearing healthcare providers to help them stay ahead in the industry. At ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to ... campaign in USA Today, which will educate readers on how to take care of ... a large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs ... on May 30th and 31st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):